RE:RE:Keytruda = $265,000 (17 doses per year)
DJDawg wrote: Hi
I may be wrong but there is also the maint protocol for the last one so more likely to be 16-20 doses total.
Nadofaragene = $313,000 (4 doses for first year; up to 16 doses over 4 years)
Oportuzumab = $310,000 (36 doses in first year)
Keytruda = $265,000 (17 doses per year)
Gemcitabine + Docetaxel = $172,000 (6 doses total) - then monthly x 10 to 24 months depending on response.
Thanks Dawg...no matter how you look at it, the current & future competition will entail a lot of doses at significant costs, both fiscal & treatment-burden wise. Cost & dosing factors will continue to play a big role in terms of ultimate commercial viability. Considering the above factors would have a net negative impact on viability, your efficacy rates better reign supreme. This certainly hasn't been the case thus far...
Current FDA approved treatments (12 month CR):
1). Valrubicin = 18%
2). Nadofaragene = 24%
3). Keytruda = 19%
Note:
1). Oportuzumab was rejected for approval by FDA (12 month CR = 18%)
2). Gemcitabine plus Docetaxel are being used off-label. This serial treatment is currently not FDA approved, however, it is frequently being used for BCG-naive high-risk NMIBC (primarily due to the BCG shortage & promising retrospective data) & also as salvage therapy for some BCG-unresponsive patients.
As you know, there is a blatantly huge opportunity staring at our faces...personally, hoping for a partnership with a well-financed, but more niche/medium-sized, pharma/tech company. Want to drive up value as much as possible before any Big Pharma tries to sink its claws into us ; ).